Breastfeeding contraindicated with Hypnomidate
The summary of product characteristics for Hypnomidate (etomidate; Janssen-Cilag) now states that etomidate has been identified in breast milk and the effect of etomidate on neonates is unknown. Breastfeeding should be discontinued during treatment and for a period of approximately 24 hours after treatment.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069545
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com